Background: Recent preclinical studies suggest that dysfunction of gastrointestinal tract may play a role in amyotrophic lateral sclerosis (ALS) pathogenesis through a modification of the gut microbiota brain axis. Our study is the first focused on microbiota analysis in ALS patients.
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Aim: Our aim was to study the main human gut microbial groups and the overall microbial diversity in ALS and healthy subjects. Moreover we have examined the influence of a treatment with a specific bacteriotherapy composed of Lactobacillus strains (Lactobacillus fermentum, Lactobacillus delbrueckii, Lactobacillus plantarum, Lactobacillus salivarius) acting on the gastrointestinal barrier.
Methods: We enrolled 50 ALS patients and 50 healthy controls, matched for sex, age, and origin. Fecal samples were used for total genomic DNA extraction. Enterobacteria, Bifidobacterium spp., Lactobacillus spp., Clostridium sensu stricto, Escherichia coli and yeast were quantified using quantitative polymerase chain reaction approach. Denaturing gradient gel electrophoresis analyses were performed to investigate total eubacteria and yeasts populations. Patients were randomized to double-blind treatment either with microorganisms or placebo for 6 months and monitored for clinical progression and microbiota composition.
Results:
The comparison between ALS subjects and healthy group revealed a variation in the intestinal microbial composition with a higher abundance of E. coli and enterobacteria and a low abundance of total yeast in patients. Polymerase chain reaction denaturing gradient gel electrophoresis analysis showed a cluster distinction between the bacterial profiles of ALS patients and the healthy subjects. The complexity of the profiles in both cases may indicate that a real dysbiosis status is not evident in the ALS patients although differences between healthy and patients exist. The effects of the progression of the disease and of the bacteriotherapy on the bacterial and yeast populations are currently in progress.
Conclusions: Our preliminary results confirm that there is a difference in the microbiota profile in ALS patients.
Key Words: probiotics, ALS, microbiota (J Clin Gastroenterol 2018;52:S68-S70) A myotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease that primarily affects the motor system and presents with progressive muscle weakness. Most patients survive for only 2 to 5 years after disease onset, often due to failure of the respiratory muscles. Currently there is no intervention that can significantly change the course of the disease. It is now recognized that ALS also involves nonmotor systems. In about 50% of cases, the degenerative process extends to the frontal and anterior temporal lobe, giving rise to a variable degree of executive dysfunction language impairments or behavioral changes. Approximately 10% of affected individuals develop frontotemporal dementia.
ALS is a familial disease in about 10% of patients, with the remaining 90% developing sporadic ALS. Toxic exposures, combined with genetic susceptibility, may trigger motor neuron degeneration explained via the gene-timeenvironment hypothesis. 1 Various cellular disturbances have been described in ALS, such as alterations in RNA proccessing, protein metabolism abnormalities, increased oxidative stress, defects in axonal transport, synaptic disorders and altered motor neuron environment, 2 which are all associated to motor neuron degeneration. Evidence of an immunoinflammatory component in ALS pathogenesis is compelling. 3 A pathologic hallmark of the neuroinflammation is prominent microglia activation at involved sites. T-regulatory lymphocytes are important immunomodulatory cells that regulate the balance between activation and suppression of the immune response.
Recent preclinical studies suggest that dysfunction of gastrointestinal tract may play a role in ALS pathogenesis through a modification of the gut microbiota brain axis. Infact, the importance of an organ called "microbiota," an ecological community of commensal, symbiotic and pathogenic microorganisms that share our bodies is emerging in the scientific literature. 4 These intestinal bacteria exert a bidirectional interaction between the gut and the central nervous system (CNS) 5 with an important role in some neurological diseases such as autism, 6 multiple sclerosis 7 or Parkinson disease (PD). In detail, in PD Scheperjans et al, 8 demonstrated a clear differences between fecal microbiota in PD patients and control subjects with a 78% lower abundance of Prevotellaceae in the fecis of PD patients (Scheperjans et al 8 ) . No detailed studies describe microbiota in Alzheimer disease and in ALS.
Gastrointestinal motor dysfunction can occur in ALS, both as delayed gastric emptying and as delayed colonic transit times. In 2015, Wu et al 9 showed in G93A transgenic mice as a model of human ALS a damaged intestinal structure and an enhanced intestinal permeability. In the same model abnormal intestinal microbiome was demonstrated. Zang et al, 10 confirmed these results and demonstrated for the first time that the ALS-causing SOD1 mutation that leads to protein aggregate formation in neurons and skeletal muscle indeed forms aggregates also in the intestine of ALS mice and human intestinal epithelial cells. These results suggest that SOD1G93A plays an essential role in pathophysiological alterations also in the intestine. The same authors treated the G93A transgenic mice with 2% butyrate, a natural bacterial product, able to restore the intestinal microbial homeostasis showing an improvement of survival and weight loss.
A hypothesis is that intestinal bacteria can represent an epigenetic entity that interacts with environmental factors (Stilling et al 11 ) in determining pathogenic influence on the CNS. Maybe there are different mechanisms by which these bacteria can affect the CNS but in particular their autoimmune role seems interesting, consisting of an alteration in circulating levels of inflammatory cytokines that can damage the CNS. This mechanism could be important in the pathogenesis of ALS; infact, the role of neuroinflammation through microglial activation and reactive astrocytosis is well demonstrated in the genesis and evolution of ALS. 12 Another mechanism by which the intestinal bacteria could enter in the ALS pathogenesis is the production of neurotoxins. Some strains of Clostridium produce neurotoxins that selectively affect the motor system. The most famous are the ones causing botulism or tetanus, but other strains such as Clostridium baratii and Clostridium butyricum produce neurotoxins, of which the effect on the nervous system is still unclear. We can assume that a colonization of ALS patients with certain species of bacteria that produce neurotoxins on the motor neuron can influence the disease in susceptible patients. An alteration in the intestinal bacterial flora as an external trigger could explain the rare cases of ALS in spouses 13 or in some clusters. 14 The use of probiotic microorganisms, typically lactobacilli and bifidobacteria, showed significant benefits not only in some gastrointestinal diseases but also in some behavioral disorders such as anxiety, depression and chronic fatigue syndrome. It is believed that these effects are related to a reduction of inflammatory cytokines 15 and oxidative stress (Innis 16 ) and a modification of nutritional status. 15 With these assumptions, our study is the first focused on microbiota analysis in ALS patients.
AIM
Our principal aim was to study the microbiota composition in ALS patients and verify the correlation with the phenotypes. Moreover we have examined the influence of a treatment with medical device acting on the gastrointestinal barrier on the microbiota composition and the progression of the disease.
METHODS
We enrolled 50 ALS patients and 50 healthy controls, matched for sex, age, and origin. Patients and controls with gastrointestinal, autoimmune or inflammatory disease were excluded. Fecal samples were used for total genomic DNA extraction using the QIAamp DNA Stool Mini Kit (Qiagen, West Sussex, UK), according to the manufacturer's instructions. Two polymerase chain reaction (PCR)-denaturing gradient gel electrophoresis analyses were performed to investigate total eubacteria and yeasts populations. They target the V2-V3 region of 16S rDNA and the D1 region of 26S rDNA, for Eubacteria and yeasts, respectively.
The bacteria belonging to Clostridium sensu stricto (C. baratii, Clostridium hystoliticum, C. butyricum, Clostridium prefringens, Clostridium botulinum, and Clostridium tetani), Enterobacteriaceae, Escherichia coli, Bifidobacterium, Lactobacillus and yeast were dosed using quantitative PCR approach targeted on 16S rRNA gene.
Patients were also randomized to double-blind treatment either to the Medical Device or placebo for 6 months and assessed by ALS Functional Rating Scale-Revised, force vital capacity (%) and body mass index. The fecal DNA, was also collected at 3 and 6 months after the baseline.
RESULTS
PCR-denaturing gradient gel electrophoresis analysis showed a clear cluster division between the bacterial profiles of ALS patients and the healthy subjects, mainly based on the presence/absence of bands in the profiles. For the yeast, the profiles was much more simpler with respect to that of Eubacteria and no unequivocal association with the presence or absence of disease could be evidenced. With a quantitative PCR analysis we observed a lower DNA concentration in patients compared with controls, with a low abundance of Clostridium and yeast, and a high abundance of E. coli and Enterobacteria. The analysis of the effects of bacterial concentrations and treatment on clinical assessment is currently in progress.
CONCLUSIONS
Our preliminary results confirm the hypothesis that microbiota is modified in ALS patients and it could contribute to the pathogenesis of the disease. Microbiota-based treatment approaches can represent a new therapeutic target.
